<DOC>
	<DOCNO>NCT01052090</DOCNO>
	<brief_summary>To evaluate safety , tolerability efficacy escalate dose PHN121 administer orally non-responder hepatitis C genotype 1 patient</brief_summary>
	<brief_title>Safety Efficacy Study Hepatitis C Patients With PHN121</brief_title>
	<detailed_description>This Phase I/II , open-label , multicenter ( 2 center ) , dose-escalation , multidose study non-responder hepatitis C genotype 1 patient . Three escalate dose level evaluate . Each cohort 6 subject enroll sequentially . Each cohort administer PHN121 orally daily 12 week . Subjects request return Week 2 , Week 4 , Week 6 , Week 9 evaluation medication . Subjects also ask return follow-up evaluation adverse event Week 12 Week 16 . Three dos plan include : 2.91 , 4.85 , 7.77 g/day . Subjects assign dose level order study entry . Initially , 6 subject enrol dose level ; 8 subject may assign dose level , depend upon dose-limiting toxicity ( DLTs ) see . Six subject start treatment dose level 1 . After sixth subject complete 84 day treatment , dose-limiting toxicity occur , next group 6 subject treat next high dose regimen . If 1 6 initial subject experience DLT , cohort subject expand 8 subject . If few two DLTs occur 8 subject , next high dose group initiate . If 2 6 initial subject 3 ( cohort 8 ) subject experience DLTs , dose escalation occur ; study discontinue MTD exceed . No subject may participate 1 cohort .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Nonsmoking adult subject age 20 year , male female NonResponder HCV patient fail achieve sustain viral response ( SVR ) , either respond relapse , prior 24week interferon base therapy Any antiviral agent discontinue least 4 week screen visit . Presence antiHCV serum Serum PCR positive HCVRNA*1 ( Genotype 1 ) Elevated ALT ( &gt; 1.3 x upper limit normal ) last 6 month ( 1.3 x 10 x upper limit normal ) screen phase No evidence show liver cirrhosis hepatocellular carcinoma*2 Hematological , biochemical serologic criterion screen phase within normal limit ( WNL ) : Hemoglobin value &gt; 12gm/dl female &gt; 13gm/dl male WBC &gt; 3,000/mm3 Neutrophil &gt; 1,500/mm3 Platelets count &gt; 90,000/mm3 Normal PT ( INR &lt; 1.2 ) Total bilirubin &lt; 2 mg/dl Albumin , WNL Serum creatinine , WNL Written inform consent Has evidence significant renal , cardiovascular , hematopoetic , neurological , pulmonary gastrointestinal pathology , medical reason disease might interfere study objective , determine investigator Has participate investigational trial within 28 day prior study enrollment Has take botanical medications*3 within 28 day prior study enrollment Has surgery within 28 day prior study enrollment Has diagnose cause liver disease chronic hepatitis C include follow condition : Coinfection HBV Hemochromatosis Alpha1 antitrypsin deficiency Wilson 's disease Autoimmune hepatitis Alcoholic liver disease Drugrelated liver disease Other liver disease consider principal investigator Has test positive HIV Has diagnose poorcontrolled Diabetes Mellitus ( HbA1C &gt; 9.0 % ) Active alcohol abuse daily intake &gt; 30 g male &gt; 20 g female within previous 1 year Active substance abuse , inhale injection drug within previous 1 year *4 Female subject child bear potential pregnant , nursing , agree practice effective birth control time period 14 day administration study drug 28 day administration study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>HCV</keyword>
</DOC>